The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

Cell. 2012 May 25;149(5):1098-111. doi: 10.1016/j.cell.2012.02.065.

Abstract

Akt kinase plays a central role in cell growth, metabolism, and tumorigenesis. The TRAF6 E3 ligase orchestrates IGF-1-mediated Akt ubiquitination and activation. Here, we show that Akt ubiquitination is also induced by activation of ErbB receptors; unexpectedly, and in contrast to IGF-1 induced activation, the Skp2 SCF complex, not TRAF6, is a critical E3 ligase for ErbB-receptor-mediated Akt ubiquitination and membrane recruitment in response to EGF. Skp2 deficiency impairs Akt activation, Glut1 expression, glucose uptake and glycolysis, and breast cancer progression in various tumor models. Moreover, Skp2 overexpression correlates with Akt activation and breast cancer metastasis and serves as a marker for poor prognosis in Her2-positive patients. Finally, Skp2 silencing sensitizes Her2-overexpressing tumors to Herceptin treatment. Our study suggests that distinct E3 ligases are utilized by diverse growth factors for Akt activation and that targeting glycolysis sensitizes Her2-positive tumors to Herceptin treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Cell Transformation, Neoplastic*
  • Disease Models, Animal
  • Drug Resistance, Neoplasm
  • F-Box Proteins / metabolism*
  • Female
  • Glycolysis*
  • Humans
  • Mice
  • Receptor, ErbB-2 / metabolism
  • S-Phase Kinase-Associated Proteins / genetics
  • S-Phase Kinase-Associated Proteins / metabolism*
  • Trastuzumab
  • Tumor Suppressor Proteins / metabolism*
  • Ubiquitination

Substances

  • Antibodies, Monoclonal, Humanized
  • F-Box Proteins
  • FBXO31 protein, human
  • S-Phase Kinase-Associated Proteins
  • Tumor Suppressor Proteins
  • Receptor, ErbB-2
  • Trastuzumab